Azenta, Inc.

Aktienanalyse zu Azenta, Inc. (AZTA)

$34.090

-2.267 (-6.65%)Zum Schluss

Loading chart…
Hoch
37.368
Eröffnung
36.520
Volumengewichteter Durchschnittskurs
34.83
Volumen
1.26M
Marktkap.
2.81B
Tief
33.030
Umsatz
43.97M
EV/EBITDA, TTM
35.56

Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company develops solutions for automated ultra-cold storage. It operates through two segments, which include Sample Management Solutions and Multiomics. The Sample Management Solutions segment operates as a single business unit offering end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Multiomics segment operates as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services. It offers a portfolio of products and sample services including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software.

www.azenta.com

KI-Analyse of Azenta, Inc. (AZTA)

Halten

Azenta Inc is currently a hold. The stock is priced at $37.72, which is above the analyst price target of $35, indicating potential overvaluation. The recent RSI of 56.115 suggests that the stock is neither overbought nor oversold, but the negative sentiment from ongoing investigations into securities claims could pose risks.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Azenta, Inc. (AZTA) beträgt 29.07, verglichen mit dem 5-Jahres-Durchschnitt von 186.71.

Erwartetes KGV

Fair bewertet
5J-Durchschnitt P/E
186.71
Aktuelles P/E
29.07
Überbewertet
487.43
Unterbewertet
-114.00

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
29.69
Aktuelles EV/EBITDA
35.56
Überbewertet
68.03
Unterbewertet
-8.64

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
4.86
Aktuelles P/S
2.51
Überbewertet
8.06
Unterbewertet
1.66

Alphio-AI-Kursszenarien für AZTA

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%AZTA

$34.77

Szenariopreis

B

Basis

Basis · 50%AZTA

$30.40

Szenariopreis

B

Bärisch

Bärisch · 25%AZTA

$25.27

Szenariopreis

Whales, die AZTA halten

A

American Capital Management, Inc.

+ HältAZTA

+1.32%

3-Monats-Rendite

Event-Zeitleiste

2026-08-24 (ET)

08:30:00

Azenta Appoints Martin Madaus as Interim CEO

08:30:00

Company Reaffirms Q4 Total Revenue Guidance

2026-08-04 (ET)

17:00:00

Company Expects Organic Revenue Flat to Up 1% for FY2025

17:00:00

Total Organic Revenue Expected to Decline in Q4 FY2025

17:00:00

Company Q3 Revenue Exceeds Expectations at $161M

News

AZTA FAQ – beantwortet von Alphio AI

Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company develops solutions for automated ultra-cold storage. It operates through two segments, which include Sample Management Solutions and Multiomics. The Sample Management Solutions segment operates as a single business unit offering end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Multiomics segment operates as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services. It offers a portfolio of products and sample services including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software. It operates in the Healthcare sector (SPECIAL INDUSTRY MACHINERY, NEC industry).

Azenta Inc is currently a hold. The stock is priced at $37.72, which is above the analyst price target of $35, indicating potential overvaluation. The recent RSI of 56.115 suggests that the stock is neither overbought nor oversold, but the negative sentiment from ongoing investigations into securities claims could pose risks.

Community

Mehr ↗
Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln